viropharma inc (VPHM:NASDAQ GS)

Financial Statements for viropharma inc (VPHM)

Currency in Millions of US Dollars	As of:	Dec 31 2009	Dec 31 2010 Reclassified	Dec 31 2011	Dec 31 2012	4 Year Trend
Revenues		310.4	439.0	544.4	427.9
TOTAL REVENUES		310.4	439.0	544.4	427.9
Cost of Goods Sold		33.3	61.3	80.0	108.5
GROSS PROFIT		277.1	377.7	464.4	319.4
Selling General & Admin Expenses, Total		89.3	95.7	127.8	174.3
R&D Expenses		52.1	39.6	66.5	67.7
Depreciation & Amortization, Total		28.2	29.4	31.0	35.3
Other Operating Expenses		--	--	3.8	4.2
OTHER OPERATING EXPENSES, TOTAL		169.6	164.6	229.1	281.6
OPERATING INCOME		107.6	213.1	235.3	37.8
Interest Expense		-11.6	-11.6	-12.6	-14.1
Interest and Investment Income		0.4	0.4	0.7	0.6
Other Non-Operating Expenses, Total		--	0.4	-2.1	3.0
Other Non-Operating Income (Expenses)		--	0.4	-2.1	3.0
Merger & Restructuring Charges		-6.9	--	--	--
Impairment of Goodwill		-65.1	--	--	--
Gain (Loss) on Sale of Investments		--	--	--	-3.8
Other Unusual Items, Total		5.7	-1.4	-13.2	-4.5
EBT, INCLUDING UNUSUAL ITEMS		30.0	200.9	208.0	19.0
Income Tax Expense		41.0	75.3	67.3	13.4
Earnings from Continuing Operations		-11.1	125.6	140.7	5.6
NET INCOME		-11.1	125.6	140.7	5.6
NET INCOME TO COMMON INCLUDING EXTRA ITEMS		-11.1	125.6	140.7	5.6
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS		-11.1	125.6	140.7	5.6

Report Data Issue

To contact VIROPHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.